Michael E. Selsted, MD, PhD

Professor of Pathology

Seth MacFarlane Professor of Immunopathology

Image of Michael E. Selsted, MD, PhD
Is this your profile? Click to edit

Overview

Dr. Selsted is a board certified pathologist, physician scientist, and administrator. His academic career includes appointments as Professor (1989-2009) and Chair of Pathology at UC Irvine School of Medicine (2000 – 2009) and Professor and Chair of Pathology in the Keck School of Medicine (2009 – 2024). Dr. Selsted leads a multidisciplinary research program focused on mammalian host defense, innate immunity, and inflammation. This focus led to the discovery and characterization of α-, β-, and θ-defensins, microbicidal and immunomodulatory peptides expressed in myeloid and epithelial cells of vertebrates. These investigations, continuously funded by NIH since 1986, have resulted in more than 50 US and foreign patents, as well as clinical translation of a θ-defensin for treatment of rheumatoid arthritis. Ongoing studies seek to elucidate the immunoregulatory mechanisms of these peptides, design and application of novel analogs, and application of θ-defensin-inspired macrocyclic peptides in models of autoimmune diseases, cancer, and infections caused by MDR bacterial and fungal pathogens.

Research Funding

  • Host defense-stimulating macrocyclic peptides for treatment of MDR bacterial infections
    NIH · R01AI125141 · May 1, 2016 – Apr 30, 2021 · Role: Principal Investigator
  • Regulation of Mucosal Immunity by Pro- and Anti-inflammatory Salivary Defensins
    NIH · R01DE021341 · Aug 12, 2010 – May 31, 2015 · Role: Principal Investigator
  • Physiologic Peptide Cyclization in Myeloid Cells
    NIH · R01AI058129 · Jun 1, 2004 – May 31, 2009 · Role: Principal Investigator
  • Molecular Ontogeny of Oral Mucosal Resistance to SIV
    NIH · R01DE015517 · Dec 15, 2003 – Nov 30, 2009 · Role: Principal Investigator
  • DRUG DISCOVERY FOR TREATMENT OF CRYPTOCOCCAL DISEASE
    NIH · U01AI031696 · Aug 1, 1991 – Jul 31, 1995 · Role: Principal Investigator
  • MOLECULAR ASPECTS OF LEUKOCYTE ANTIMICROBIAL PEPTIDES
    NIH · R37AI022931 · Jul 1, 1989 – Mar 31, 2012 · Role: Principal Investigator
  • Molecular Aspects of Leukocyte Antimicrobial Peptides
    NIH · R01AI022931 · Jul 1, 1986 – May 31, 2019 · Role: Principal Investigator

Publications

  • The macrocyclic peptide rhesus theta defensin 1 activates interferon and antiviral pathways in human monocytes. J Leukoc Biol. 2025 Dec 01; 117(12).. View in PubMed
  • An ADAM10 Exosite Inhibitor Is Efficacious in an In Vivo Collagen-Induced Arthritis Model. Pharmaceuticals (Basel). 2024 Jan 09; 17(1).. View in PubMed
  • RTD-1 therapeutically normalizes synovial gene signatures in rat autoimmune arthritis and suppresses proinflammatory mediators in RA synovial fibroblasts. Physiol Genomics. 2019 12 01; 51(12):657-667.. View in PubMed
  • Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms. Sci Rep. 2019 11 15; 9(1):16905.. View in PubMed
  • Essential role of IFN-γ in T cell-associated intestinal inflammation. JCI Insight. 2018 09 20; 3(18).. View in PubMed
  • Fungicidal Potency and Mechanisms of θ-Defensins against Multidrug-Resistant Candida Species. Antimicrob Agents Chemother. 2018 06; 62(6).. View in PubMed
  • Rhesus θ-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment. Am J Respir Cell Mol Biol. 2018 03; 58(3):310-319.. View in PubMed
  • Macrocyclic θ-defensins suppress tumor necrosis factor-α (TNF-α) shedding by inhibition of TNF-α-converting enzyme. J Biol Chem. 2018 02 23; 293(8):2725-2734.. View in PubMed
  • Suppression and resolution of autoimmune arthritis by rhesus θ-defensin-1, an immunomodulatory macrocyclic peptide. PLoS One. 2017; 12(11):e0187868.. View in PubMed
  • Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. Antimicrob Agents Chemother. 2017 08; 61(8).. View in PubMed